Mirum Pharmaceuticals (MIRM) Insider Trading & Ownership $41.51 +0.38 (+0.92%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.87%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$115,064.40Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$1.66 M Get MIRM Insider Trade Alerts Want to know when executives and insiders are buying or selling Mirum Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MIRM Insider Buying and Selling by Quarter Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Mirum Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/14/2024Jolanda HoweSVPSell2,500$47.10$117,750.00 9/18/2024Patrick J HeronDirectorBuy115$37.40$4,301.00 9/6/2024Patrick J HeronDirectorBuy230$41.58$9,563.40 7/2/2024Jolanda HoweSVPSell375$34.00$12,750.00 6/24/2024Pamela VigInsiderSell30,559$34.00$1,039,006.00 6/5/2024Saira RamasastryDirectorSell5,000$25.68$128,400.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/27/2024Eric BjerkholtCFOBuy2,000$24.80$49,600.00 3/25/2024Peter RadovichCOOSell4,303$25.80$111,017.40 3/18/2024Eric BjerkholtCFOBuy2,000$25.80$51,600.00 2/2/2024Jolanda HoweSVPSell735$26.19$19,249.65 1/8/2024Christopher PeetzCEOSell5,209$28.03$146,008.27 1/8/2024Jolanda HoweSVPSell528$28.04$14,805.12 1/8/2024Lara LongpreInsiderSell1,019$28.04$28,572.76 1/8/2024Peter RadovichCOOSell1,408$28.03$39,466.24 (Data available from 1/1/2013 forward) MIRM Insider Trading Activity - Frequently Asked Questions Who is on Mirum Pharmaceuticals's Insider Roster? The list of insiders at Mirum Pharmaceuticals includes Christopher Peetz, Eric Bjerkholt, James E Flynn, Jolanda Howe, Lara Longpre, Michael G. Grey, Niall O'donnell, Pamela Vig, Patrick J Heron, Peter Radovich, and Saira Ramasastry. Learn more on insiders at MIRM. What percentage of Mirum Pharmaceuticals stock is owned by insiders? 22.87% of Mirum Pharmaceuticals stock is owned by insiders. Learn more on MIRM's insider holdings. Which Mirum Pharmaceuticals insiders have been buying company stock? The following insiders have purchased MIRM shares in the last 24 months: Eric Bjerkholt ($397,700.00), and Patrick J Heron ($4,040,644.25). How much insider buying is happening at Mirum Pharmaceuticals? Insiders have purchased a total of 167,023 MIRM shares in the last 24 months for a total of $4,438,344.25 bought. Which Mirum Pharmaceuticals insiders have been selling company stock? The following insiders have sold MIRM shares in the last 24 months: Christopher Peetz ($287,031.97), Jolanda Howe ($359,754.09), Lara Longpre ($54,325.36), Michael G. Grey ($863,936.00), Pamela Vig ($1,039,006.00), Peter Radovich ($187,034.89), and Saira Ramasastry ($128,400.00). How much insider selling is happening at Mirum Pharmaceuticals? Insiders have sold a total of 95,261 Mirum Pharmaceuticals shares in the last 24 months for a total of $2,919,488.31 sold. Mirum Pharmaceuticals Key ExecutivesMr. Christopher Peetz (Age 45)Co-Founder, CEO and Director Compensation: $1.31MMr. Peter Radovich M.B.A. (Age 46)Ph.D., COO & President Compensation: $881.8kMr. Eric H. Bjerkholt M.B.A. (Age 64)Chief Financial Officer Compensation: $600.4kDr. Pamela Vig Ph.D. (Age 53)Chief Scientific Officer Compensation: $678.2kAndrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 56)Senior Vice President of Human Resources Ms. Lara Longpre MBA (Age 54)MSC, Chief Development Officer Compensation: $678.2kMs. Vinita P. KumarSenior vice President of QualityDr. Jean-Luc Girardet Ph.D.Senior Vice President of Technical Operations More Insider Trading Tools from MarketBeat Related Companies Revolution Medicines Insider Trading Lantheus Insider Trading Nuvalent Insider Trading Blueprint Medicines Insider Trading Elanco Animal Health Insider Trading Cytokinetics Insider Trading TG Therapeutics Insider Trading Viking Therapeutics Insider Trading BridgeBio Pharma Insider Trading Crinetics Pharmaceuticals Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:MIRM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.